세계 감염증 치료제 시장 규모는 2024년부터 2031년까지 예측 기간 동안 연평균 5.76%의 CAGR을 기록하며 2023년 21,080억 9,000만 달러에서 2031년 1,691억 5,000만 달러 규모로 성장할 것으로 예상됩니다.
2022년 감염병으로 인한 사망자 수는 COVID-19에 이어 결핵이 두 번째로 많으며, COVID-19는 124만 명, 결핵은 113만 명, HIV/AIDS는 63만 명, 말라리아는 62만 명이 사망할 것으로 예상됩니다. 전 세계 의료 산업은 바이러스, 바이러스, 박테리아 등 다양한 감염성 병원체로 인한 전염병으로 인해 큰 압박을 받고 있습니다. 진단 및 치료법의 발전, 위생 상태의 개선, 백신 접종, 항균제 치료 등으로 감염으로 인한 사망자 수는 감소하고 있지만, 감염증의 증가와 재발은 여전히 전 세계 보건 환경에 영향을 미치고 있습니다. 감염증 치료제 시장은 감염병 발생 건수 증가, 감염병 조기 진단에 대한 인식 증가, 다양한 민간 및 정부 기관의 연구 및 자금 지원 활동의 활성화로 인해 예측 기간 동안 크게 성장할 것으로 예상됩니다.
감염병 유병률 및 사망률 증가
감염병 유병률의 증가는 개발도상국에서의 감염증 치료제 판매를 촉진할 것으로 예상됩니다. 또한, 신흥국의 의료 연구 및 생명과학 분야에 대한 막대한 투자는 선진 기술의 채택을 촉진하여 감염성 질환의 진단 및 치료를 촉진하고 있습니다.
정부의 노력
세계 각국 정부는 다양한 노력을 통해 감염증 치료제 시장 발전에 적극적으로 참여하고 있습니다. 이러한 노력은 새로운 건강 문제를 해결하고 감염병 발생에 대한 대비책을 마련하기 위한 것입니다. 각국 정부는 R&D에 많은 자금을 투입하여 혁신적인 치료제를 개발하고자 하는 제약사 및 학술 기관을 지원하고 있습니다. 또한, 규제 기관은 새로운 치료법의 사용을 촉진하기 위해 승인 절차를 간소화하는 데 중요한 역할을 하고 있습니다.
분자진단 기술, 특히 PCR의 우월성
핵산증폭검사, PCR은 앞으로 더욱 확산될 분자진단 기술 중 하나이며, PCR은 병원체 검출에 가장 널리 사용되는 핵산증폭법으로 감염성 질환, 세균성 질환, 소화기 질환, 성병의 조기 진단에 중요한 도구가 되고 있습니다.
세계 감염증 치료제 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global infectious disease therapeutics market is projected to witness a CAGR of 5.76% during the forecast period 2024-2031, growing from USD 108.09 billion in 2023 to USD 169.15 billion in 2031. Infectious diseases have a significant impact on the global healthcare market, leading to economic, social, and health-related consequences. Tuberculosis accounted for the second highest deaths from infectious disease in 2022 after COVID-19. COVID-19, tuberculosis, HIV/AIDS, and malaria accounted for 1.24 million, 1.13 million, 0.63 million, and 0.62 million deaths respectively. The global healthcare industry is under significant pressure due to infectious diseases, which are caused by various infectious agents such as viruses, viroids, and bacteria. Although advanced diagnosis and treatment options, as well as improvements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases, the rise and re-occurrence of infectious diseases continue to affect global health outcome. The infectious disease therapeutics market is expected to grow significantly over the forecast period due to rising infectious disease occurrences, increased awareness about early infectious disease diagnosis, and increased research and funding activities by various private and government organizations.
For instance, WHO launched a global network to detect and prevent infectious disease threats in 2023. Not only does this initiative provide a platform to connect countries and regions, but it also improves the system for analyzing and collecting samples from around the globe, which will help and improve the public healthcare sector in decision-making and welfare.
Increasing Prevalence and Mortality Rate of Infectious Diseases
The increasing prevalence of infectious diseases is expected to drive the sales of infectious disease therapeutics in developing nations. Furthermore, significant investments in health research and life sciences in emerging countries are facilitating the adoption of advanced technologies, thereby promoting the diagnosis and treatment of infectious diseases. Morbidity and mortality are mainly caused due to infectious diseases. Such diseases are the cause of more than 33% or 52 million annual deaths, globally. Nearly half of the global population is at risk of recurring infectious diseases.
Countries, such as India, South Korea, Brazil, and Mexico, have a high burden of infectious diseases like Hepatitis, HAI, HIV, and influenza. As a result, medical device companies are increasing investments and manufacturing capacities in these countries to meet the demand for diagnostic devices and instruments over the forecast period.
Viral Therapeutics are Dominating the Market
In 2022, viral therapeutics held the second-largest market share in the infectious disease therapeutics sector. The significant share held by this segment is attributed to the growing prevalence of viral diseases like hepatitis and HIV, the increasing number of clinical trials for new drug launches, and initiatives aimed at enhancing drug adoption. Hepatitis and human papillomavirus patients are increasing at a rapid rate globally. Due to the rapid increase in the prevalence and incidence of infectious diseases, medical device manufacturers are prioritizing innovation and manufacturing capacities.
The World Health Organization's (WHO) Global Health Sector Strategy on viral hepatitis aims to test and treat a large proportion of individuals with HBV and HCV by 2030. In January 2023, the Serum Institute of India launched 'CERVAVAC,' the first Quadrivalent Human Papillomavirus vaccine made in India, in collaboration with DBT, BIRAC, and the Bill and Melinda Gates Foundation. This vaccine is India's first indigenously developed vaccine for the prevention of cervical cancer. This vaccine is affordable and cost effective and the government of India has taken initiatives to make it accessible for everyone in the country.
Government Initiatives
Governments around the globe have been actively engaged in fostering advancements within the infectious disease therapeutics market through various initiatives. These efforts aim to address emerging health challenges and ensure preparedness for infectious outbreaks. Governments often allocate substantial funding for research and development, supporting pharmaceutical companies and academic institutions with their objective of developing innovative therapeutics. Additionally, regulatory bodies play a crucial role in streamlining the approval process to expedite the availability of new treatments. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, and vector borne diseases, along with emerging or re-emerging threats like influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures. The Program supports R&D projects to achieve the Sustainable Development Goals Target to combat various water-borne diseases, communicable diseases, and hepatitis and end the epidemics of viral diseases like AIDS, TB, and malaria by the year 2030.
Dominance of Molecular Diagnostic Techniques, Especially PCR
Nucleic Acid amplification tests, PCR, are a few molecular diagnostic techniques that are going to be more popular in the coming frame of time. PCR is the most widely used nucleic acid amplification method for pathogen detection and has become an important tool in the early diagnosis of infectious diseases, bacterial infections, GI infections, and sexually transmitted diseases.
Thermo Fisher launched real-time PCR kits for the detection of infectious diseases in India in February 2023. The TaqPath PCR kits provide assurance and consistency for the creation and examination of diagnostic tests for infectious diseases. Genetic risk factor identification, therapy response monitoring, and disease screening are a few patient care practices that can be now carried out using the TaqPath PCR kits developed by Thermo Fisher.
North America Dominates Infectious Disease Therapeutics Market
North America is dominating the infectious diseases therapeutics market due to the increasing prevalence of infectious diseases, improving healthcare infrastructure, the presence of key market players, and rising awareness programs. Government initiatives and their effort towards providing the country with adequate infrastructure and facilities, such as trained professionals, high-end medical devices, and drugs, are creating lucrative market opportunities in the region. Other factors accelerating the market demand in North America includes the growing prevalence of such diseases, favorable reimbursement scenarios, the presence of numerous manufacturers in the U.S., and an increasing number of clinical trials for developing new treatment drugs and devices. According to the Centers for Disease Control and Prevention, in the United States., influenza and pneumonia caused 41,917 deaths in 2022.
Future Market Scenario (2024 - 2031F)
The future market scenario for treatments for infectious diseases is expected to be dynamic, driven by continued technological development and a greater emphasis on preventive measures. More individualized and efficient treatments are expected by the ongoing development of precision medicine, which is made possible by advancements in genomics and personalized therapies. Novel treatments for infectious diseases are being made possible by developments in immunotherapy and antiviral drugs, which are changing the market landscape. The COVID-19 pandemic has expedited the development, production, and distribution of vaccines, enabling a more responsive approach to newly emerging infectious diseases.
Key Players Landscape and Outlook
The global market for infectious disease therapeutics is fiercely competitive and somewhat fragmented. To stay ahead, major industry players continuously implement various growth strategies such as innovations, mergers, acquisitions, collaborations, and partnerships. Additionally, they focus on research and development to provide the most effective and economical solutions. Most prominent players of this market, such as Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Bayer AG, Janssen Pharmaceutical, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc., are the ones mostly bringing new innovations and robust technology in the market.
In January 2023, Thermo Fisher Scientific Inc. (US) introduced the CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This kit is designed to detect genomic mutations in HIV-1 viral ribonucleic acid extracted from plasma or dried blood spots, specifically analyzing mutations in the protease, reverse transcriptase, and integrase regions of the pol gene.
Roche introduced the Elecsys HCV Duo in July 2022. This immunoassay enables the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
May & Baker Nigeria Plc launched Artelum Combo, a new drug to combat malaria parasites across Nigeria in March 2022. The medicine is a unique combination of Arthemeter Lumefantrine and Paracetamol, providing complete malaria therapy in a single package.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work